| Title |
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, April 2018
|
| DOI | 10.1007/s00280-018-3577-9 |
| Pubmed ID | |
| Authors |
Masato Ozaka, Hiroshi Ishii, Tosiya Sato, Makoto Ueno, Masafumi Ikeda, Kazuhiro Uesugi, Naohiro Sata, Kouichirou Miyashita, Nobumasa Mizuno, Kunihiro Tsuji, Takuji Okusaka, Junji Furuse |
| Abstract |
We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for chemotherapy-naïve patients with metastatic pancreatic cancer. Patients with untreated metastatic pancreatic cancer (MPC) received modified FOLFIRINOX (intravenous oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, 5-FU infusion 2400 mg/m2 over 46 h, no bolus 5-FU). The primary endpoints were overall survival and the incidence of grade 3 or higher neutropenia. No patients received prophylactic pegfilgrastim. Sixty-nine pts. were enrolled from 39 institutions in Japan. The median overall survival was 11.2 months [95% confidence interval (CI) 9.0-]. The median progression-free survival was 5.5 months (95% CI 4.1-6.7). The response rate was 37.7% (95% CI 26.3-50.2), and the disease control rate was 78.3% (95% CI 66.7-87.3). The incidence of grade 3 or higher neutropenia was 47.8%. Serious adverse events occurred in six patients (8.7%). All AE proportions were less than those in the previous Japanese full-dose phase II study. One patient died due to interstitial pneumonia related to treatment. This is the first prospective study of modified FOLFIRINOX in Asia. Modified FOLFIRINOX in this study has an improved safety profile with maintained efficacy in MPC without prophylactic pegfilgrastim. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 91 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 20% |
| Other | 16 | 18% |
| Student > Ph. D. Student | 8 | 9% |
| Student > Doctoral Student | 5 | 5% |
| Student > Master | 4 | 4% |
| Other | 11 | 12% |
| Unknown | 29 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Agricultural and Biological Sciences | 2 | 2% |
| Arts and Humanities | 1 | 1% |
| Other | 4 | 4% |
| Unknown | 34 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2018.
All research outputs
#18,550,468
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#1,988
of 2,501 outputs
Outputs of similar age
#241,632
of 330,814 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#14
of 24 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,814 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.